Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALRNNASDAQ:CTMXNASDAQ:ELDNNASDAQ:KOD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALRNAileron Therapeutics$2.52$1.61▼$4.40$45.72M2.2482,284 shs63,385 shsCTMXCytomX Therapeutics$2.40+12.7%$1.06$0.40▼$2.64$193.49M1.112.13 million shs5.24 million shsELDNEledon Pharmaceuticals$3.15$3.09$2.30▼$5.54$188.63M0.08273,122 shs135,600 shsKODKodiak Sciences$3.50-2.2%$3.31$1.92▼$11.60$184.67M2.42347,208 shs173,413 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALRNAileron Therapeutics0.00%0.00%0.00%0.00%-38.12%CTMXCytomX Therapeutics+12.68%+17.65%+239.03%+255.45%+34.08%ELDNEledon Pharmaceuticals0.00%0.00%-3.96%-22.79%+22.09%KODKodiak Sciences-2.23%-1.13%-16.86%-12.72%+16.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALRNAileron TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACTMXCytomX Therapeutics4.4144 of 5 stars3.52.00.04.73.22.51.3ELDNEledon Pharmaceuticals2.7549 of 5 stars3.54.00.00.03.61.70.0KODKodiak Sciences4.0985 of 5 stars3.03.00.04.61.83.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALRNAileron Therapeutics 4.00Strong BuyN/AN/ACTMXCytomX Therapeutics 3.00Buy$5.33122.22% UpsideELDNEledon Pharmaceuticals 3.00Buy$12.50296.83% UpsideKODKodiak Sciences 2.00Hold$9.00157.14% UpsideCurrent Analyst Ratings BreakdownLatest ALRN, ELDN, KOD, and CTMX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025CTMXCytomX TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$2.50 ➝ $5.005/15/2025CTMXCytomX TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$5.00 ➝ $5.005/12/2025CTMXCytomX TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.00 ➝ $6.004/14/2025CTMXCytomX TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$3.25 ➝ $2.503/31/2025KODKodiak SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.003/7/2025CTMXCytomX TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.003/7/2025CTMXCytomX TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALRNAileron TherapeuticsN/AN/AN/AN/A$1.41 per shareN/ACTMXCytomX Therapeutics$147.56M1.31N/AN/A($0.71) per share-3.38ELDNEledon PharmaceuticalsN/AN/AN/AN/A$0.30 per shareN/AKODKodiak SciencesN/AN/AN/AN/A$5.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALRNAileron Therapeutics-$15.73M-$3.120.00N/AN/AN/A-74.08%-27.93%N/ACTMXCytomX Therapeutics-$570K$0.4814.12N/AN/A10.96%-41.47%8.11%8/14/2025 (Estimated)ELDNEledon Pharmaceuticals-$116.54M-$2.10N/AN/AN/AN/A-189.99%-28.17%N/AKODKodiak Sciences-$260.49M-$3.63N/AN/AN/AN/A-84.52%-45.40%8/13/2025 (Estimated)Latest ALRN, ELDN, KOD, and CTMX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ELDNEledon Pharmaceuticals-$0.28-$0.08+$0.20-$0.08N/AN/A5/14/2025Q1 2025KODKodiak Sciences-$0.89-$1.09-$0.20-$1.09N/AN/A5/12/2025Q1 2025CTMXCytomX Therapeutics$0.18$0.27+$0.09$0.27$35.42 million$50.92 million3/27/2025Q4 2024KODKodiak Sciences-$0.90-$0.84+$0.06-$0.84N/AN/A3/20/2025Q4 2024ELDNEledon Pharmaceuticals-$0.32-$0.64-$0.32-$0.64N/AN/A3/6/2025Q4 2024CTMXCytomX Therapeutics-$0.23$0.22+$0.45$0.22$13.53 million$38.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALRNAileron TherapeuticsN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALRNAileron TherapeuticsN/A3.303.30CTMXCytomX TherapeuticsN/A1.041.04ELDNEledon PharmaceuticalsN/A6.536.53KODKodiak SciencesN/A8.428.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALRNAileron Therapeutics90.89%CTMXCytomX Therapeutics67.77%ELDNEledon Pharmaceuticals56.77%KODKodiak Sciences89.06%Insider OwnershipCompanyInsider OwnershipALRNAileron Therapeutics5.10%CTMXCytomX Therapeutics7.00%ELDNEledon Pharmaceuticals12.30%KODKodiak Sciences45.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALRNAileron Therapeutics921.67 million20.56 millionNot OptionableCTMXCytomX Therapeutics17080.62 million72.78 millionOptionableELDNEledon Pharmaceuticals1059.88 million52.75 millionOptionableKODKodiak Sciences9052.76 million28.79 millionOptionableALRN, ELDN, KOD, and CTMX HeadlinesRecent News About These CompaniesKodiak Sciences Q2 EPS Forecast Decreased by HC WainwrightMay 23, 2025 | marketbeat.comAnalysts Issue Forecasts for Kodiak Sciences Q2 EarningsMay 23, 2025 | americanbankingnews.comPoint72 Asset Management L.P. Buys New Shares in Kodiak Sciences Inc. (NASDAQ:KOD)May 22, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Reduces Position in Kodiak Sciences Inc. (NASDAQ:KOD)May 17, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Invests $902,000 in Kodiak Sciences Inc. (NASDAQ:KOD)May 17, 2025 | marketbeat.comKodiak Sciences (KOD) Projected to Post Earnings on WednesdayMay 16, 2025 | marketbeat.comKodiak Sciences Inc.: Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial ResultsMay 15, 2025 | finanznachrichten.deKodiak Sciences Shares Drop After Wider-Than-Expected 1Q LossMay 15, 2025 | marketwatch.comKodiak Q1 Loss Wider Than Expected, Pipeline Development in FocusMay 15, 2025 | zacks.comKodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial ResultsMay 14, 2025 | prnewswire.comWhy Kodiak Sciences Inc.’s (KOD) Stock Is Down 15.35%May 7, 2025 | aaii.comBlackRock, Inc. Reduces Stake in Kodiak Sciences Inc.May 6, 2025 | gurufocus.comKodiak Sciences Inc. (NASDAQ:KOD) Shares Purchased by Price T Rowe Associates Inc. MDMay 5, 2025 | marketbeat.comBoxer Capital Management LLC Invests $9.95 Million in Kodiak Sciences Inc. (NASDAQ:KOD)May 4, 2025 | marketbeat.comMore companies announce ARVO 2025 presentationsMay 2, 2025 | ophthalmologytimes.comKodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular DiseasesMay 1, 2025 | prnewswire.comTCG Crossover Management LLC Buys 137,380 Shares of Kodiak Sciences Inc. (NASDAQ:KOD)May 1, 2025 | marketbeat.comNantahala Capital Management LLC Has $2.65 Million Stock Holdings in Kodiak Sciences Inc. (NASDAQ:KOD)April 30, 2025 | marketbeat.com1,139,527 Shares in Kodiak Sciences Inc. (NASDAQ:KOD) Purchased by Adage Capital Partners GP L.L.C.April 30, 2025 | marketbeat.comSeismologists monitoring string of Kodiak-area quakesApril 29, 2025 | alaskapublic.orgSeismic noise tracks sea-ice changesApril 18, 2025 | kodiakdailymirror.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALRN, ELDN, KOD, and CTMX Company DescriptionsAileron Therapeutics NASDAQ:ALRNAileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.CytomX Therapeutics NASDAQ:CTMX$2.40 +0.27 (+12.68%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$2.48 +0.08 (+3.13%) As of 06:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Eledon Pharmaceuticals NASDAQ:ELDN$3.15 0.00 (0.00%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$3.15 0.00 (0.00%) As of 05/28/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Kodiak Sciences NASDAQ:KOD$3.50 -0.08 (-2.23%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$3.72 +0.22 (+6.40%) As of 05/28/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
